What is the difference between Sandostatin and Sandostatin LAR?

Sandostatin is the short-acting form given by subcutaneous or intravenous injection every 8 hours. It is used for acute bleeding (esophageal varices) or to stabilize patients before switching to long-acting therapy. Sandostatin LAR Depot is a long-acting release formulation given by intramuscular injection every 4 weeks, designed for chronic maintenance therapy in acromegaly and neuroendocrine tumors.

Does octreotide cure neuroendocrine tumors?

No. Octreotide controls symptoms (flushing, diarrhea) and may slow tumor growth, but it does not cure neuroendocrine tumors. The PROMID trial showed it prolonged time to tumor progression by approximately 8 months in well-differentiated metastatic midgut NETs. For curative intent, surgery is required when feasible. Lutetium-177 DOTATATE (a radiolabeled somatostatin analog) is used for progressive disease.

Treatment hubFDA ApprovedDeep Dive

Octreotide Treatment Guide: Sandostatin, Sandostatin LAR Depot, Cost and Provider Paths

In the United States, Octreotide is an FDA-approved peptide therapy. Acromegaly; carcinoid tumors; vasoactive intestinal peptide tumors (VIPomas); control of symptoms related to metastatic neuroendocrine tumors

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by James Patterson, MD, Board-Certified in Sports Medicine and Physical Medicine & Rehabilitation.

Last reviewed: April 27, 2026

Overview

Octreotide is a synthetic cyclic octapeptide analog of somatostatin, approved by the FDA for acromegaly, carcinoid tumors, and vasoactive intestinal peptide (VIP)-secreting tumors. It is one of the most important peptide drugs in oncology and endocrinology.

Approved Product Paths

Sandostatin

Branded octreotide pathway. Acromegaly; carcinoid tumors; vasoactive intestinal peptide tumors (VIPomas); control of symptoms related to metastatic neuroendocrine tumors

Sandostatin LAR Depot

Branded octreotide pathway. Acromegaly; carcinoid tumors; vasoactive intestinal peptide tumors (VIPomas); control of symptoms related to metastatic neuroendocrine tumors

Benefits

•First-line medical therapy for acromegaly
•Controls hormone hypersecretion in neuroendocrine tumors
•Prolongs time to tumor progression in metastatic midgut NETs (PROMID trial)
•Treats esophageal variceal bleeding (acute hemorrhage)

Side Effects & Friction

•GI symptoms (nausea, bloating, diarrhea, steatorrhea)
•Gallstones and biliary sludge (long-term use)
•Hyperglycemia (inhibits insulin and glucagon)
•Bradycardia and cardiac conduction abnormalities

Administration Routes

Subcutaneous injection · Intramuscular injection · Intravenous

Cost Reality

Octreotide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in immune support who can evaluate whether Octreotide fits the patient's clinical profile and insurance constraints.

How Octreotide Works

Octreotide is a synthetic octapeptide analog of somatostatin. It binds to somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5) to inhibit growth hormone secretion, suppress GI hormone release, and reduce splanchnic blood flow.

Octreotide mimics native somatostatin but has a longer half-life and greater receptor selectivity for SSTR2 and SSTR5. It suppresses GH secretion from the pituitary, making it effective for acromegaly.

In the gastrointestinal tract, octreotide inhibits secretion of gastrin, cholecystokinin, secretin, motilin, vasoactive intestinal peptide (VIP), and insulin. This reduces pancreatic and intestinal secretions, slows motility, and decreases splanchnic blood flow.

The reduction in splanchnic blood flow and portal pressure makes octreotide valuable for acute variceal bleeding and certain portal hypertensive complications.

In neuroendocrine tumors (NETs), octreotide suppresses hormone secretion from tumor cells expressing SSTR2, controlling symptoms of carcinoid syndrome, VIPoma, glucagonoma, and gastrinoma.

The short-acting formulation requires subcutaneous injection 2-3 times daily. The long-acting release (LAR) intramuscular formulation uses microspheres to release drug over 4 weeks, improving adherence.

Octreotide does not cure NETs but controls hormonal symptoms and may have antiproliferative effects in some tumor types.

Somatostatin receptor 2 (SSTR2)Somatostatin receptor 5 (SSTR5)Pituitary somatotrophsGI endocrine cellsSplanchnic vasculature

Clinical Trial Evidence

Acromegaly trials

PMID: 7685251

Population: Patients with active acromegaly

N= 150

Duration: 6-12 months

Endpoint: GH and IGF-1 normalization

GH <2.5 ng/mL achieved in ~60% of patients
IGF-1 normalization in ~50%
Tumor shrinkage observed in ~30%
LAR formulation showed equivalent efficacy to TID dosing

PROMID (NET antiproliferative)

PMID: 18728079

Population: Patients with metastatic midgut neuroendocrine tumors

N= 85

Duration: Median 6 years

Endpoint: Time to tumor progression

Median time to progression: 14.3 months vs 6.0 months placebo (HR 0.34)
First trial to demonstrate antiproliferative effect of somatostatin analogs in NETs
Stable disease achieved in ~66% of treated patients

Dosing & Administration

Acromegaly (Sandostatin LAR)Intramuscular · Every 4 weeks

Starting: 20 mg every 4 weeks

Titration: May increase to 30 mg every 4 weeks if GH/IGF-1 not controlled

Maintenance: 20-30 mg every 4 weeks

Maximum: 30 mg every 4 weeks

•Administered by healthcare professional via deep intramuscular injection
•Use gluteal muscle; rotate sites
•Short-acting octreotide may be used for 2 weeks after LAR initiation until therapeutic levels achieved
•Monitor GH and IGF-1 every 3-6 months

Neuroendocrine tumors (Sandostatin LAR)Intramuscular · Every 3-4 weeks

Starting: 20-30 mg every 4 weeks

Titration: May increase to 30 mg every 3 weeks for refractory symptoms

Maintenance: 20-30 mg every 3-4 weeks

Maximum: 30 mg every 3 weeks

•Same administration as for acromegaly
•Symptom control usually evident within 1-2 weeks of LAR injection
•For breakthrough symptoms, short-acting rescue doses may be used
•Monitor tumor markers and imaging every 3-6 months

Side Effect Profile

Gastrointestinal

Diarrheamild8%

Paradoxical; usually transient

Abdominal painmild8%

Usually mild

Nauseamild7%

Transient

Flatulencemild5%

Common

Metabolic

Gallstones/cholelithiasismoderate20-30%

Long-term use; usually asymptomatic; requires ultrasound monitoring

Hyperglycemiamoderate5%

Somatostatin inhibits insulin and glucagon; monitor glucose

Hypothyroidismmoderate2%

TSH suppression; monitor thyroid function

Cardiac

Bradycardiamoderate3%

Sinus bradycardia; usually asymptomatic

Injection site

Painmild5%

IM injection discomfort

Contraindications & Warnings

Do Not Use

Hypersensitivity to octreotide or components

Important Warnings

Gallbladder effects: inhibits gallbladder contractility and bile secretion; increases risk of gallstones with long-term use. Obtain gallbladder ultrasound annually.
Hyper- and hypoglycemia: somatostatin inhibits both insulin and glucagon; glucose dysregulation possible. Monitor blood glucose, especially at initiation and dose changes.
Cardiac conduction abnormalities: bradycardia and arrhythmias reported. Use caution in patients with cardiac disease.
Thyroid function: may suppress TSH secretion. Monitor thyroid function periodically.
Fat malabsorption and B12 deficiency with long-term use in some patients.

Drug Interactions

Drug	Interaction	Severity	Mechanism
Cyclosporine	Reduced absorption	major	Octreotide may reduce cyclosporine bioavailability; monitor levels
Bromocriptine	Increased bromocriptine levels	moderate	Octreotide may increase bromocriptine bioavailability
Insulin/oral hypoglycemics	Unpredictable glucose effects	moderate	Somatostatin inhibits insulin and glucagon; glucose may rise or fall
QT-prolonging drugs	Additive QT risk	moderate	Octreotide may prolong QT interval in susceptible patients

Monitoring Requirements

GH and IGF-1 every 3-6 months (acromegaly)
Gallbladder ultrasound annually
Fasting glucose and HbA1c at baseline and periodically
Thyroid function tests (TSH, free T4) annually
Vitamin B12 annually with long-term use
Heart rate and ECG if cardiac history
Tumor markers and imaging every 3-6 months (NETs)

How Octreotide Compares

EfficacyLanreotide (Somatuline) advantage

Octreotide: Similar GH/IGF-1 control

Lanreotide (Somatuline): Similar efficacy

Both SSTR2-selective somatostatin analogs with comparable outcomes

DosingLanreotide advantage

Octreotide: Monthly IM (LAR)

Lanreotide: Monthly deep SC (autogel)

Both monthly; patient preference for IM vs SC varies

MechanismPegvisomant (Somavert) advantage

Octreotide: Somatostatin analog (suppresses GH secretion)

Pegvisomant (Somavert): GH receptor antagonist (blocks GH action)

Pegvisomant normalizes IGF-1 in ~90% vs ~50% for octreotide

CostOctreotide advantage

Octreotide: ~$3,000/month

Pegvisomant: ~$8,000-12,000/month

Octreotide is significantly less expensive

RoleSurgery advantage

Octreotide: Medical therapy or adjunct

Surgery: Definitive treatment for resectable tumors

Surgery first-line if accessible; octreotide for residual disease or when surgery contraindicated

Evidence Quality Assessment

Overall Evidence Grade: A

A = Strong evidence from multiple large RCTs

Human RCTs: Extensive: Acromegaly trials, PROMID NET trial, multiple NET symptom control studies

Long-term data: Good: PROMID 6-year data; decades of clinical use

Real-world evidence: Extensive: Standard of care for acromegaly and NETs for decades

Regulatory status: FDA-approved for acromegaly, carcinoid syndrome, and VIPoma

Is Octreotide Right for You?

Ideal Candidates

Acromegaly patients with persistent disease after surgery or who are not surgical candidates
Neuroendocrine tumor patients with hormonal symptoms (carcinoid syndrome, VIPoma)
NET patients with SSTR2-positive tumors requiring antiproliferative therapy
Patients with acute variceal bleeding (short-acting only)

Avoid

Patients with complete surgical cure of acromegaly
SSTR2-negative neuroendocrine tumors (will not respond)
Uncontrolled diabetes (may worsen glucose control)
Severe cardiac conduction disease

Use With Caution

Diabetes or prediabetes
History of gallbladder disease
Cardiac disease or bradycardia
Thyroid disease
Patients requiring cyclosporine

Cost & Insurance Deep Dive

List Price (Monthly)

~$3,000-$4,000/month (LAR)

Cash-Pay Range

$2,500-$4,000/month

Insurance Coverage Rate

~80-90% for approved indications (acromegaly, NETs)

Prior Auth Likelihood

High; requires diagnosis confirmation and often treatment failure documentation

Savings Programs

Novartis patient assistanceFree for eligible patients

Eligibility: Uninsured, income ≤400% FPL

Annual application

Copay assistanceMay reduce out-of-pocket significantly

Eligibility: Commercially insured

Not for government insurance

Cost-Effectiveness Notes

•Standard of care for acromegaly and NET symptom control; cost justified by clinical benefit
•PROMID demonstrated tumor progression delay, supporting antiproliferative use
•No generic LAR formulation available; biosimilar development limited
•Monthly injection reduces burden compared to older TID regimens

Ready to find a octreotide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a octreotide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Octreotide FAQ

Sources

1. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
J Clin Oncol • 2009
Claim type: clinical
View source →
2. FDA Information on Octreotide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.